Soleus Capital Management, L.P. Viking Therapeutics, Inc. Transaction History

Soleus Capital Management, L.P.

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 15, 2024	SELL	$17.4 - $94.5 $6.42 Million - $34.9 Million	-369,079 Reduced 84.61%	67,121 $5.5 Million
Q4 2023 Feb 14, 2024	BUY	$9.24 - $19.64 $2.9 Million - $6.17 Million	314,000 Added 256.96%	436,200 $8.12 Million
Q3 2023 Nov 14, 2023	SELL	$10.92 - $16.0 $2.34 Million - $3.43 Million	-214,500 Reduced 63.71%	122,200 $1.35 Million
Q2 2023 Aug 14, 2023	SELL	$14.84 - $24.79 $1.83 Million - $3.06 Million	-123,300 Reduced 26.8%	336,700 $5.46 Million
Q1 2023 May 15, 2023	BUY	$8.08 - $17.33 $3.72 Million - $7.97 Million	460,000 New	460,000 $7.66 Million

478

66.1M

6.24M

3.01M

Ticker VKTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,688,496
Market Cap $5.05B
Description
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trial...

Get notified when there are updates to the investment portfolio of Soleus Capital Management, L.P., based on Form 13F filings with the SEC.

Stay updated on Soleus Capital Management, L.P. with notifications on news.